Boston Scientific announced today the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. INTREPID is a prospective, multi-center, double-blinded, randomized, controlled study to evaluate the safety and effectiveness of motor function and overall quality of life in patients with the Vercise DBS System for the treatment of Parkinson’s disease.
Not new, but recently came across while researching some information about related devices… The NASA Tech Briefs of May 1999 described a device that telemeters pressure changes to detect intrauterine contractions. According to the brief: A biotelemetric system for monitoring key physiological parameters of a fetus and its uterine environment is undergoing development. The main